[Expression of markers of immunocompetent cells, cytokine level, and L-arginine metabolism in complex extremely high frequency and interferon therapy of inflammatory diseases in women of highlands].
Chronic inflammatory gynecological diseases (CIGD) in highlanders (2,100-2,200 m a.s.l.) are accompanied with the following changes in immunoregulatory parameters: strengthening in the expression of CD3+ (TCR), CD4+ (T-helpers), CD16+ (NK-cells), CD25+ (activated IL-2R), increase in CD4+/CD8+ ratio, levels of circulating cytokines--alpha-, beta-, gamma-interferon (IFN) and alpha-, beta-tumor necrotizing factor (TNF), strengthening in immune adhesion of thrombocytes (IAT), and inhibition of the oxidative metabolic way of L-arginine with redistribution of the main metabolites formed via its non-oxidative way. Complex extremely high frequency (EHF) therapy and interferon (with Laferon) therapy of CIGD normalized expression of the differentiated and functional CD-markers of immunocompetent cells (ICC), CD4+/CD8+ ratio, increased expression of CD8+, decreased IAT and levels of circulating cytokines (IFN, TNF), changed L-arginine metabolism with activation of the oxidative way. Full-value of the population signs of immune stabilization due to the treatment was complemented with increase in the ICC functional parameters--markers of mitochondrial, lysosomal and mitotic activity. We first demonstrated a high effectiveness of complex use of EHF and Laferon as an immunocorrective therapy of CIGD in highlanders.
Taradiĭ
N N
NN
Kabardino-Balkar State University, Nalchik, Russia.
Bagdasarova
I V
IV
Uzdenova
Z Kh
ZKh
Bichekueva
F Kh
FKh
Doloman
L B
LB
Kotsiuruba
A V
AV
Krivokhatskaia
L D
LD
Kamenetskaia
O V
OV
Mandziuk
Ia P
IaP
Volkova
L N
LN
D000328:Adult; D000531:Altitude; D015703:Antigens, CD / Q000097:blood; D001120:Arginine / Q000378:metabolism*; D015415:Biomarkers / Q000097:blood; D003131:Combined Modality Therapy; D003583:Cytokinins / Q000097:blood*; D005260:Female; D006801:Humans; D000860:Hypoxia / Q000378:metabolism; D007370:Interferon Type I / Q000627:therapeutic use*; D016898:Interferon-alpha; D007694:Killer Cells, Natural / Q000378:metabolism; D008872:Microwaves / Q000627:therapeutic use*; D008875:Middle Aged; D000292:Pelvic Inflammatory Disease / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D011946:Receptors, Antigen / Q000096:biosynthesis; D011994:Recombinant Proteins; D006377:T-Lymphocytes, Helper-Inducer / Q000378:metabolism
D015703:Antigens, CD; D015415:Biomarkers; D003583:Cytokinins; D007370:Interferon Type I; D016898:Interferon-alpha; D011946:Receptors, Antigen; D011994:Recombinant Proteins; C076799:interferon-alpha 8; D001120:Arginine